FinalDose — Programmable DNA-Targeted Cancer Therapy Platform

FinalDose is developing a programmable drug platform that uses DNA sequence recognition to identify and destroy cancer cells while leaving healthy cells untouched, starting with a modality aimed at all cancers. Founded in 2025 and based in San Francisco, the company is backed by Y Combinator (Spring 2026).

• Founded: 2025
• HQ: San Francisco, CA
• Sector: Precision Oncology / Programmable Therapeutics
• Funding Stage: Y Combinator Seed (Spring 2026)
• Notable Backers: Y Combinator

Core Data Grid

FinalDose Leadership & Structural Breakdown

• Key Leadership: Jeff Liu (CEO) — Oxford PhD in Oncology, previously founded Vivid Dx (sepsis diagnostics) which raised $15M. Li-Yao Huang (CSO) — Biochemistry background, built Cas9-based therapeutic target discovery pipelines. Steven Lin (CTO) — Computational biology, led UK Biobank genetic susceptibility analysis during COVID.
• Primary Competitors: Beam Therapeutics, CRISPR Therapeutics, Insitro
• Core Use Cases & Market Problem: Patients with cancers driven by specific genetic mutations where current protein-targeted therapies have limited reach. The platform targets the DNA level to expand the addressable mutation space and improve precision of cell elimination.

Plain English Explanation

FinalDose is building a “smart” drug molecule that reads a cell’s DNA like a barcode. If it detects the exact genetic sequence associated with cancer, it activates and kills only that cell. Healthy cells without the matching sequence remain unaffected.

Target Customers & Adoption Context

Oncology clinicians and cancer treatment centers seeking more precise therapies that can address a wider range of genetic drivers than current targeted drugs. The approach is designed for cancers where traditional small-molecule or antibody therapies have struggled due to “undruggable” protein targets.

Capital & Traction Signals

Y Combinator Spring 2026 acceptance provides early validation and resources. The founding team of three Oxford PhDs brings deep domain expertise across oncology, biochemistry, and computational biology. CEO Jeff Liu’s prior startup (Vivid Dx) successfully raised $15M, demonstrating execution capability in diagnostics/therapeutics-adjacent spaces. The company is actively building its programmable cell-elimination platform with an initial focus on broad cancer applicability.

Editorial Assessment (Investor Lens)

FinalDose targets a long-standing limitation in oncology: the inability of most drugs to act directly at the DNA level for precise, mutation-specific cell killing. By going one layer deeper than protein-targeted therapies, the platform could unlock a significantly larger set of genetic drivers. The Oxford PhD founding team with prior fundraising success and relevant technical pipelines (Cas9 work, large-scale genetic analysis) provides credible scientific grounding at this early stage. YC backing adds network and credibility signals. Key watchpoints include the inherent technical and regulatory risks of novel therapeutic modalities, long development timelines typical in oncology, and competition from established gene-editing and targeted therapy players. The combination of a differentiated mechanism and strong founder pedigree offers asymmetric potential if the programmable DNA-recognition approach demonstrates reliable in vivo performance and a clear path toward broad applicability across mutation-driven diseases.

Last Updated: June 2026

Sources

• finaldose.ai
• Y Combinator company page and launch announcement
• LinkedIn company and founder profiles
• Public statements on platform mechanism